141 related articles for article (PubMed ID: 34941588)
1. New Indication for Ruxolitinib.
Aschenbrenner DS
Am J Nurs; 2022 Jan; 122(1):20. PubMed ID: 34941588
[TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience.
Xue E; Lorentino F; Pavesi F; Assanelli A; Peccatori J; Bernardi M; Corti C; Ciceri F; Lupo Stanghellini MT
Leuk Res; 2021 Oct; 109():106642. PubMed ID: 34157510
[TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients.
Wei C; Zhang X; Liang D; Yang J; Du J; Yue C; Deng L
Drug Des Devel Ther; 2021; 15():4875-4883. PubMed ID: 34880598
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre.
Leung GMK; Sim JPY; Hwang YY; Chan TSY; Lie AKW; Tse E; Kwong YL
Ann Hematol; 2022 Jan; 101(1):155-163. PubMed ID: 34767056
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia.
Zhang B; Chen L; Zhou J; Zu Y; Gui R; Li Z; Wang J; Yu F; Zhang Y; Zhao H; Ji Z; Song Y
Sci Rep; 2021 Apr; 11(1):8501. PubMed ID: 33875780
[TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib for Chronic Graft-versus-Host Disease.
Shibusawa M
N Engl J Med; 2021 Oct; 385(17):1631. PubMed ID: 34670052
[No Abstract] [Full Text] [Related]
7. Ruxolitinib for Chronic Graft-versus-Host Disease.
Gratwohl A
N Engl J Med; 2021 Oct; 385(17):1631. PubMed ID: 34670051
[No Abstract] [Full Text] [Related]
8. Ruxolitinib for Chronic Graft-versus-Host Disease. Reply.
Zeiser R; Teshima T; Locatelli F
N Engl J Med; 2021 Oct; 385(17):1631-1632. PubMed ID: 34670053
[No Abstract] [Full Text] [Related]
9. Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease.
Abedin SM; Hamadani M
Expert Opin Investig Drugs; 2020 May; 29(5):423-427. PubMed ID: 32293938
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy.
Le RQ; Wang X; Zhang H; Li H; Przepiorka D; Vallejo J; Leong R; Ma L; Goldberg KB; Pazdur R; Theoret MR; De Claro A
Oncologist; 2022 Jun; 27(6):493-500. PubMed ID: 35363318
[TBL] [Abstract][Full Text] [Related]
11. Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis.
Abedin S; Rashid N; Schroeder M; Romee R; Nauffal M; Alhaj Moustafa M; Kharfan-Dabaja MA; Palmer J; Hogan W; Hefazi M; Larson S; Holtan S; DeFilipp Z; Jayani R; Dholaria B; Pidala J; Khimani F; Grunwald MR; Butler C; Hamadani M
Br J Haematol; 2021 Nov; 195(3):429-432. PubMed ID: 34254289
[TBL] [Abstract][Full Text] [Related]
12. New Indication for Ibrutinib.
Aschenbrenner DS
Am J Nurs; 2017 Dec; 117(12):22. PubMed ID: 29189239
[No Abstract] [Full Text] [Related]
13. Fecal microbiota transplantation with ruxolitinib as a treatment modality for steroid-refractory/dependent acute, gastrointestinal graft-versus-host disease: A case series.
Biliński J; Jasiński M; Tomaszewska A; Lis K; Kacprzyk P; Chmielewska L; Karakulska-Prystupiuk E; Mullish BH; Basak GW
Am J Hematol; 2021 Dec; 96(12):E461-E463. PubMed ID: 34587331
[No Abstract] [Full Text] [Related]
14. Ruxolitinib add-on therapy in steroid-refractory graft-vs-host disease following hematopoietic cell transplantation: A single institutional experience.
Wang YL; Chang TY; Wen YC; Yang SH; Hsiao YW; Chen SH; Jaing TH
Pediatr Neonatol; 2024 Jan; 65(1):85-86. PubMed ID: 37951828
[No Abstract] [Full Text] [Related]
15. Efficacy and feasibility of ruxolitinib in chronic steroid-refractory GVHD in a pediatric intestine transplant.
Ghobrial S; Gonzalez C; Yazigi N; Kaufman S; Matsumoto C; Fishbein T; Hawksworth J; Kroemer A; Khan K
Pediatr Transplant; 2021 May; 25(3):e13836. PubMed ID: 32981124
[TBL] [Abstract][Full Text] [Related]
16. Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease.
Pusic I; Lee C; Veeraputhiran M; Minor C; DiPersio JF
Bone Marrow Transplant; 2024 Feb; 59(2):282-284. PubMed ID: 38071272
[No Abstract] [Full Text] [Related]
17. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT.
Kröger N; Sbianchi G; Sirait T; Wolschke C; Beelen D; Passweg J; Robin M; Vrhovac R; Helbig G; Sockel K; Conneally E; Rubio MT; Beguin Y; Finke J; Bernasconi P; Morozova E; Clausen J; von dem Borne P; Schaap N; Schroyens W; Patriarca F; Di Renzo N; Yeğin ZA; Hayden P; McLornan D; Yakoub-Agha I
Leukemia; 2021 Dec; 35(12):3551-3560. PubMed ID: 34023851
[TBL] [Abstract][Full Text] [Related]
18. Beyond ruxolitinib in steroid-refractory acute graft-versus-host disease.
Lee CJ; Pusic I; Savani BN
Br J Haematol; 2021 Nov; 195(3):306-307. PubMed ID: 34402041
[No Abstract] [Full Text] [Related]
19. Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib.
Saraceni F; Scortechini I; Mancini G; Mariani M; Federici I; Gaetani M; Barbatelli P; Minnucci ML; Bagnarelli P; Olivieri A
Transpl Infect Dis; 2021 Feb; 23(1):e13401. PubMed ID: 32629531
[TBL] [Abstract][Full Text] [Related]
20. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib.
Foss FM; Rubinowitz A; Landry ML; Isufi I; Gowda L; Seropian S; Perreault S; Shenoi SV
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):720-723. PubMed ID: 32727701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]